The global keloid treatment market reached US$ 3.8 billion in 2023 and is expected to enjoy a valuation of US$ 5.6 billion by the end of 2033. Furthermore, with the rising prevalence of keloid worldwide, the overall demand for keloid treatment is set to record a 3.8% CAGR between 2023 and 2033.
Among various types of treatments, the intralesional corticosteroid injections segment dominated the global keloid treatment market with a share of about 28.3% in 2021, and the trend is likely to continue during the forecast period.
Keloids and hypertrophic scars are caused by cutaneous injury and irritation, including trauma, insect bite, burn, surgery, vaccination, skin piercing, acne, folliculitis, chicken pox, and herpes zoster infection.
Scars can be treated in various ways with varying degrees of success. Nonsurgical treatments, which aim to slow the appearance of scars, enhance their looks, and restore function, have become of utmost importance.
Factors such as an increase in road accidents and burn cases, advancements in keloid treatment approaches, and the rising popularity of aesthetic surgeries are playing crucial roles in accelerating the growth of the keloid treatment market.
The global market formed around 29.5% of the overall US$ 14.1 billion global scar treatment market in 2021, and this number is likely to increase further during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Advancements in Keloid Treatments to Present an Array of Opportunities for Market Growth
In addition to the already available conventional treatment options, improvements in the knowledge of the molecular mechanisms underlying keloids and hypertrophic scars have ushered in a new age of drug discovery and the development of novel, emerging anti-pathologic scar treatments.
Interferons, which have successfully treated high-risk melanomas, are one of a few emerging treatments widely used in various skin conditions like condyloma acuminate and basal cell carcinoma.
Verapamil, an antihypertensive medication, works on keloids and hypertrophic scars by lowering calcium levels inside the cells, for patients with keloids, autologous fat grafting (also known as lipotransfer) of adipose tissue-derived stem cells (ADSCs) has been proven to enhance scar texture, pliability volume, and elasticity.
Mesenchymal stem cells (MSCs) have shown a solid ability to enhance the healing of wounds and regeneration by secreting differentiation and growth factors that promote migration, angiogenesis, up-regulate epithelialization, and collagen remodeling.
Over the projected years, market participants are estimated to have access to a wide range of profitable growth prospects due to the availability of keloid treatments.
Restraining Factors Limit the Global Market Growth
Many therapeutic approaches have been explored to prevent and reduce keloids and hypertrophic scars, but none are beneficial in all patients. There is currently no recognized global standard of care for treatment, and the evidence-based literature is limited.
Keloid and hypertrophic scars are a constant issue for patients and clinicians despite the many targeted options that are currently available. No one therapy has, as of now, been regarded as the gold standard for all excessive scarring, nor has it been able to eliminate scarring. These factors are estimated to continue, therefore harming the overall market growth.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 3.8% |
| Market Valuation (2023) | US$ 3.8 billion |
| Market Valuation (2033) | US$ 5.6 billion |
The global market secured a 3.5% CAGR in the historical period of 2022 to 2022. The market captured a valuation of US$ 3.1 billion in 2018 and US$ 3.5 billion in 2022.
Increasing incidence of wound and injury-related cases, rise in aesthetic surgeries being performed worldwide, and growing adoption of various keloid treatments are key factors expected to drive growth in the global market. Similarly, a rising preference for minimally invasive procedures is estimated to further accelerate the growth of the keloid treatment market during the next ten years.
Clinicians have assessed the potential of anti-inflammatory and chemotherapeutic molecules to inhibit keloid recurrence and conducted studies to enhance the use of conventional therapies, such as steroids and radiation. Cryotherapy and lasers, two procedure-focused medicines, have also effectively lowered keloid symptomatology.
Keloids are distinguished as being more clinically severe than hypertrophic scars, commonly causing itching and pain in patients. In contrast to hypertrophic scars, which can heal naturally over the years, keloids grow to produce thick, stiff scars that seldom heal on their own. The fundamental elements of keloid pathogenesis have attracted much attention since keloids can be distressing for patients.
The variety of therapies available for the prevention and treatment of keloids is constantly growing, and optimistic technological breakthroughs from innovative methodologies have contributed to this growth. Reliable information about the consistent use of the various injectable therapies and devices reported in the literature can be collected as doctors get more experience using them.
There currently need to be accepted standards for keloid management that have the approval of an academic governing body. As a result, there are many prospects for research and development of treatment modalities to provide a variety of treatments for keloids as a standardized measure of care in the market for keloid treatment.
Increasing investments in research & development in this sphere are expected to create lucrative growth opportunities for leading providers during the forecast period.
Principal Consultant
As per FMI, the intralesional corticosteroid injections segment is expected to register a higher CAGR of 2.5% between 2023 and 2033, accounting for a market share of about 27.9% in the global market in 2033. Due to their higher effectiveness, it can be attributed to patients' rising preference for intralesional corticosteroid injections.
The most often used treatment option for keloid scars is the intralesional injection, preferably separately or in combination with 5-FU, verapamil, and bleomycin. It is considered the gold standard in the nonsurgical treatment of hypertrophic and keloid scars.
The hospital's segment held a higher market share value of around 37.1% in 2023 and is poised to capture a higher growth rate during the assessment period. This can be attributed to the rise in hospitals worldwide and the easy availability of various keloid treatments at lower prices in government hospitals.
The rising inclination of patients to opt for keloid treatments in hospitals due to the presence of well-trained medical professionals is estimated to bode well for the market growth during the forecast period.
| Countries | Forecast Share |
|---|---|
| United States | 30.9% |
| Germany | 6.9% |
| Japan | 5.8% |
| Countries | Forecast CAGR |
|---|---|
| Australia | 3.0% |
| China | 4.1% |
| India | 3.7% |
| United Kingdom | 4.6% |
Rise in Cases of Burn Injuries and Road Accidents to Bolster Market Growth in the United States
The United States dominates the global market by securing a share of about 30.9% and is expected to continue to experience the same growth throughout the forecast period.
Growth in the United States market is driven by the rising prevalence of accidents, injuries, dermal illnesses, highly sophisticated healthcare facilities, and high levels of healthcare awareness among people.
According to a report published in 2016 by the American Burn Association, around 486,000 burn injury cases were reported in the United States that received medical treatment. This rise in burn accidents is expected to foster the growth of keloid treatment in the country during the assessment period.
Booming Medical Tourism Pushing Demand for Keloid Treatments in Germany
As per FMI, the global market in Germany is set to exhibit a share of nearly 6.9% during the forecast period owing to the flourishing medical tourism, advanced equipment for dermatology and cosmetic procedures, and increasing spending by people on cosmetic procedures.
Similarly, the rapid expansion of the healthcare industry and the increasing prevalence of keloid disorder among the German population is estimated to bode well for the keloid market during the assessment period.
Increasing Investments in Research & Development to Supplement Market Growth in China
China is likely to hold a market share of around 4.1% in the global market in 2023 and is anticipated to witness a steady growth rate during the forecast period. There are vast developments in research-based activities within the country, and this factor is expected to provide traction to the overall market growth.
Moreover, with a high population density and favorable government support, the country is expected to provide a large share of revenue within the global market throughout the forecast years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global market is highly fragmented due to numerous rivals in this space. Leading businesses employ mergers and acquisitions, alliances and collaborations, and new product releases to satisfy consumer demand and increase their client base.
Some recent developments in the global market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Region, Treatment, End Use |
| Key Companies Profiled | Novartis AG; Sensus Healthcare; RXi Pharmaceuticals, Inc.; Sonoma Pharmaceuticals, Inc.; Perrigo Company plc.; Bristol-Myers Squibb Company; Pacific World Corporation; Valeant Pharmaceuticals International, Inc.; Revitol Corporation; Avita Medical Limited |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Through 2033, the market anticipates to continue to develop at a CAGR of 3.8%.
By 2033, the market is projected to flourish to a value of US$ 5.6 billion.
In 2023, the market is projected to be worth US$ 3.8 billion.
From 2018 to 2022, the global market attained a CAGR of 3.5%.
Innovations in keloid treatments may provide various market growth opportunities.
Through 2033, the United Kingdom is projected to evolve at a CAGR of 4.6%%.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Occlusive Dressing 5.3.2. Compression Therapy 5.3.3. Cryosurgery 5.3.4. Excision 5.3.5. Radiation Therapy 5.3.6. Laser Therapy 5.3.7. Interferon Therapy 5.3.8. Intralesional Corticosteroid Injections 5.3.9. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Dermatology Clinics 6.3.3. Ambulatory Surgical Centers (ASCs) 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By End User 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Treatment 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By End User 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Treatment 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By End User 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Treatment 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By End User 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment 14.2.3. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment 15.1.2.2. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment 15.2.2.2. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment 15.3.2.2. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment 15.4.2.2. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment 15.5.2.2. By End User 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment 15.6.2.2. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment 15.7.2.2. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment 15.8.2.2. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment 15.9.2.2. By End User 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment 15.10.2.2. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment 15.11.2.2. By End User 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment 15.12.2.2. By End User 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment 15.13.2.2. By End User 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment 15.14.2.2. By End User 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment 15.15.2.2. By End User 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment 15.16.2.2. By End User 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment 15.17.2.2. By End User 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment 15.18.2.2. By End User 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment 15.19.2.2. By End User 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment 15.20.2.2. By End User 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment 15.21.2.2. By End User 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Treatment 15.22.2.2. By End User 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Treatment 15.23.2.2. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment 16.3.3. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Novartis AG 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Sensus Healthcare 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. RXi Pharmaceuticals, Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Sonoma Pharmaceuticals, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Perrigo Company plc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Bristol-Myers Squibb Company 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Pacific World Corporation 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Valeant Pharmaceuticals International, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Revitol Corporation 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Avita Medical Limited 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Keloid Treatment Market
